A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation

Silvia Rossi, Caterina Motta, Valeria Studer, Fabrizia Monteleone, Valentina De Chiara, Fabio Buttari, Francesca Barbieri, Giorgio Bernardi, Luca Battistini, Gary Cutter, Olaf Stüve, Marco Salvetti, Diego Centonze

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Multiple sclerosis (MS) patients discontinuing natalizumab treatment are at risk of disease reactivation. No clinical or surrogate parameters exist to identify patients at risk of post-natalizumab MS reactivation. Objective: To determine the role of natalizumab-induced lymphocytosis and of Akt polymorphisms in disease reactivation after natalizumab discontinuation. Methods: Peripheral leukocyte count and composition were monitored in 93 MS patients during natalizumab treatment, and in 56 of these subjects who discontinued the treatment. Genetic variants of the anti-apoptotic protein Akt were determined in all subjects because natalizumab modulates the apoptotic pathway and lymphocyte survival is regulated by the apoptotic cascade. Results: Natalizumab-induced peripheral lymphocytosis protected from post-natalizumab MS reactivation. Subjects who relapsed or had magnetic resonance imaging (MRI) worsening after treatment cessation, in fact, had milder peripheral lymphocyte increases during the treatment, largely caused by less marked T cell increase. Furthermore, subjects carrying a variant of the gene coding for Akt associated with reduced anti-apoptotic efficiency (rs2498804T) had lower lymphocytosis and higher risk of disease reactivation. Conclusion: This study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment, and with the risk of disease reactivation after natalizumab discontinuation.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
JournalMultiple Sclerosis
Volume19
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Lymphocytosis
Apoptosis Regulatory Proteins
Multiple Sclerosis
Natalizumab
Lymphocytes
Therapeutics
Withholding Treatment
Lymphocyte Count
Leukocyte Count
Magnetic Resonance Imaging
T-Lymphocytes

Keywords

  • Apoptosis
  • CIRIS
  • lymphocytosis
  • rebound
  • relapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. / Rossi, Silvia; Motta, Caterina; Studer, Valeria; Monteleone, Fabrizia; De Chiara, Valentina; Buttari, Fabio; Barbieri, Francesca; Bernardi, Giorgio; Battistini, Luca; Cutter, Gary; Stüve, Olaf; Salvetti, Marco; Centonze, Diego.

In: Multiple Sclerosis, Vol. 19, No. 1, 01.2013, p. 59-68.

Research output: Contribution to journalArticle

Rossi, S, Motta, C, Studer, V, Monteleone, F, De Chiara, V, Buttari, F, Barbieri, F, Bernardi, G, Battistini, L, Cutter, G, Stüve, O, Salvetti, M & Centonze, D 2013, 'A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation', Multiple Sclerosis, vol. 19, no. 1, pp. 59-68. https://doi.org/10.1177/1352458512448106
Rossi, Silvia ; Motta, Caterina ; Studer, Valeria ; Monteleone, Fabrizia ; De Chiara, Valentina ; Buttari, Fabio ; Barbieri, Francesca ; Bernardi, Giorgio ; Battistini, Luca ; Cutter, Gary ; Stüve, Olaf ; Salvetti, Marco ; Centonze, Diego. / A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. In: Multiple Sclerosis. 2013 ; Vol. 19, No. 1. pp. 59-68.
@article{bc019dae0d8d4de99bf2a7b3d604173f,
title = "A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation",
abstract = "Background: Multiple sclerosis (MS) patients discontinuing natalizumab treatment are at risk of disease reactivation. No clinical or surrogate parameters exist to identify patients at risk of post-natalizumab MS reactivation. Objective: To determine the role of natalizumab-induced lymphocytosis and of Akt polymorphisms in disease reactivation after natalizumab discontinuation. Methods: Peripheral leukocyte count and composition were monitored in 93 MS patients during natalizumab treatment, and in 56 of these subjects who discontinued the treatment. Genetic variants of the anti-apoptotic protein Akt were determined in all subjects because natalizumab modulates the apoptotic pathway and lymphocyte survival is regulated by the apoptotic cascade. Results: Natalizumab-induced peripheral lymphocytosis protected from post-natalizumab MS reactivation. Subjects who relapsed or had magnetic resonance imaging (MRI) worsening after treatment cessation, in fact, had milder peripheral lymphocyte increases during the treatment, largely caused by less marked T cell increase. Furthermore, subjects carrying a variant of the gene coding for Akt associated with reduced anti-apoptotic efficiency (rs2498804T) had lower lymphocytosis and higher risk of disease reactivation. Conclusion: This study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment, and with the risk of disease reactivation after natalizumab discontinuation.",
keywords = "Apoptosis, CIRIS, lymphocytosis, rebound, relapse",
author = "Silvia Rossi and Caterina Motta and Valeria Studer and Fabrizia Monteleone and {De Chiara}, Valentina and Fabio Buttari and Francesca Barbieri and Giorgio Bernardi and Luca Battistini and Gary Cutter and Olaf St{\"u}ve and Marco Salvetti and Diego Centonze",
year = "2013",
month = "1",
doi = "10.1177/1352458512448106",
language = "English (US)",
volume = "19",
pages = "59--68",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation

AU - Rossi, Silvia

AU - Motta, Caterina

AU - Studer, Valeria

AU - Monteleone, Fabrizia

AU - De Chiara, Valentina

AU - Buttari, Fabio

AU - Barbieri, Francesca

AU - Bernardi, Giorgio

AU - Battistini, Luca

AU - Cutter, Gary

AU - Stüve, Olaf

AU - Salvetti, Marco

AU - Centonze, Diego

PY - 2013/1

Y1 - 2013/1

N2 - Background: Multiple sclerosis (MS) patients discontinuing natalizumab treatment are at risk of disease reactivation. No clinical or surrogate parameters exist to identify patients at risk of post-natalizumab MS reactivation. Objective: To determine the role of natalizumab-induced lymphocytosis and of Akt polymorphisms in disease reactivation after natalizumab discontinuation. Methods: Peripheral leukocyte count and composition were monitored in 93 MS patients during natalizumab treatment, and in 56 of these subjects who discontinued the treatment. Genetic variants of the anti-apoptotic protein Akt were determined in all subjects because natalizumab modulates the apoptotic pathway and lymphocyte survival is regulated by the apoptotic cascade. Results: Natalizumab-induced peripheral lymphocytosis protected from post-natalizumab MS reactivation. Subjects who relapsed or had magnetic resonance imaging (MRI) worsening after treatment cessation, in fact, had milder peripheral lymphocyte increases during the treatment, largely caused by less marked T cell increase. Furthermore, subjects carrying a variant of the gene coding for Akt associated with reduced anti-apoptotic efficiency (rs2498804T) had lower lymphocytosis and higher risk of disease reactivation. Conclusion: This study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment, and with the risk of disease reactivation after natalizumab discontinuation.

AB - Background: Multiple sclerosis (MS) patients discontinuing natalizumab treatment are at risk of disease reactivation. No clinical or surrogate parameters exist to identify patients at risk of post-natalizumab MS reactivation. Objective: To determine the role of natalizumab-induced lymphocytosis and of Akt polymorphisms in disease reactivation after natalizumab discontinuation. Methods: Peripheral leukocyte count and composition were monitored in 93 MS patients during natalizumab treatment, and in 56 of these subjects who discontinued the treatment. Genetic variants of the anti-apoptotic protein Akt were determined in all subjects because natalizumab modulates the apoptotic pathway and lymphocyte survival is regulated by the apoptotic cascade. Results: Natalizumab-induced peripheral lymphocytosis protected from post-natalizumab MS reactivation. Subjects who relapsed or had magnetic resonance imaging (MRI) worsening after treatment cessation, in fact, had milder peripheral lymphocyte increases during the treatment, largely caused by less marked T cell increase. Furthermore, subjects carrying a variant of the gene coding for Akt associated with reduced anti-apoptotic efficiency (rs2498804T) had lower lymphocytosis and higher risk of disease reactivation. Conclusion: This study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment, and with the risk of disease reactivation after natalizumab discontinuation.

KW - Apoptosis

KW - CIRIS

KW - lymphocytosis

KW - rebound

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=84872289860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872289860&partnerID=8YFLogxK

U2 - 10.1177/1352458512448106

DO - 10.1177/1352458512448106

M3 - Article

C2 - 22577119

AN - SCOPUS:84872289860

VL - 19

SP - 59

EP - 68

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 1

ER -